Percutaneous thermal ablation for renal cell carcinoma in patients with Birt–Hogg–Dubé syndrome

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: The purpose of this study was to analyze the outcome of patients with Birt–Hogg–Dubé (BHD) syndrome who underwent percutaneous thermal ablation of renal cell carcinoma (RCC). Materials and methods: Six patients with genetically proven BHD syndrome who underwent one or more sessions of percutaneous thermal ablation for the treatment of RCC were included. There were 4 men and 2 women, with a mean age of 57.3 ± 7.5 [SD] years (range: 44–67 years). A total of 29 RCCs (1–16 tumors per patient) were treated during 20 thermal ablation sessions (7 with radiofrequency ablation and 13 with cryoablation). Outcomes of thermal ablation therapy were assessed, including technical success, adverse events, local tumor progression, development of metastases, survival after thermal ablation, and changes in renal function. Results: Technical success was achieved in all ablation sessions (success rate, 100%). No grade 4 or 5 adverse events were observed. All patients were alive with no distant metastasis during a median follow-up period of 54 months (range: 6–173 months). No local tumor progression was found. The mean decrease in estimated glomerular filtration rate during follow-up was 10.7 mL/min/1.73 m2. No patients required dialysis or renal transplantation. Conclusion: Radiofrequency ablation and cryoablation show promising results for the treatment of RCCs associated with BHD syndrome. Percutaneous thermal ablation may be a useful treatment option for this rare hereditary condition.

Original languageEnglish
JournalDiagnostic and Interventional Imaging
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Renal Cell Carcinoma
Hot Temperature
Cryosurgery
Neoplasm Metastasis
Neoplasms
Therapeutics
Glomerular Filtration Rate
Kidney Transplantation
Dialysis
Kidney
Survival

Keywords

  • Birt–Hogg–Dubé syndrome
  • Cryoablation
  • Percutaneous thermal ablation
  • Radiofrequency ablation
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{d7f2de06cf4c4ef3a9bea1b01f136a3b,
title = "Percutaneous thermal ablation for renal cell carcinoma in patients with Birt–Hogg–Dub{\'e} syndrome",
abstract = "Purpose: The purpose of this study was to analyze the outcome of patients with Birt–Hogg–Dub{\'e} (BHD) syndrome who underwent percutaneous thermal ablation of renal cell carcinoma (RCC). Materials and methods: Six patients with genetically proven BHD syndrome who underwent one or more sessions of percutaneous thermal ablation for the treatment of RCC were included. There were 4 men and 2 women, with a mean age of 57.3 ± 7.5 [SD] years (range: 44–67 years). A total of 29 RCCs (1–16 tumors per patient) were treated during 20 thermal ablation sessions (7 with radiofrequency ablation and 13 with cryoablation). Outcomes of thermal ablation therapy were assessed, including technical success, adverse events, local tumor progression, development of metastases, survival after thermal ablation, and changes in renal function. Results: Technical success was achieved in all ablation sessions (success rate, 100{\%}). No grade 4 or 5 adverse events were observed. All patients were alive with no distant metastasis during a median follow-up period of 54 months (range: 6–173 months). No local tumor progression was found. The mean decrease in estimated glomerular filtration rate during follow-up was 10.7 mL/min/1.73 m2. No patients required dialysis or renal transplantation. Conclusion: Radiofrequency ablation and cryoablation show promising results for the treatment of RCCs associated with BHD syndrome. Percutaneous thermal ablation may be a useful treatment option for this rare hereditary condition.",
keywords = "Birt–Hogg–Dub{\'e} syndrome, Cryoablation, Percutaneous thermal ablation, Radiofrequency ablation, Renal cell carcinoma",
author = "Y. Matsui and T. Hiraki and H. Gobara and T. Iguchi and K. Tomita and M. Uka and M. Araki and Y. Nasu and M. Furuya and S. Kanazawa",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.diii.2019.06.009",
language = "English",
journal = "Diagnostic and interventional imaging",
issn = "2211-5684",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Percutaneous thermal ablation for renal cell carcinoma in patients with Birt–Hogg–Dubé syndrome

AU - Matsui, Y.

AU - Hiraki, T.

AU - Gobara, H.

AU - Iguchi, T.

AU - Tomita, K.

AU - Uka, M.

AU - Araki, M.

AU - Nasu, Y.

AU - Furuya, M.

AU - Kanazawa, S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: The purpose of this study was to analyze the outcome of patients with Birt–Hogg–Dubé (BHD) syndrome who underwent percutaneous thermal ablation of renal cell carcinoma (RCC). Materials and methods: Six patients with genetically proven BHD syndrome who underwent one or more sessions of percutaneous thermal ablation for the treatment of RCC were included. There were 4 men and 2 women, with a mean age of 57.3 ± 7.5 [SD] years (range: 44–67 years). A total of 29 RCCs (1–16 tumors per patient) were treated during 20 thermal ablation sessions (7 with radiofrequency ablation and 13 with cryoablation). Outcomes of thermal ablation therapy were assessed, including technical success, adverse events, local tumor progression, development of metastases, survival after thermal ablation, and changes in renal function. Results: Technical success was achieved in all ablation sessions (success rate, 100%). No grade 4 or 5 adverse events were observed. All patients were alive with no distant metastasis during a median follow-up period of 54 months (range: 6–173 months). No local tumor progression was found. The mean decrease in estimated glomerular filtration rate during follow-up was 10.7 mL/min/1.73 m2. No patients required dialysis or renal transplantation. Conclusion: Radiofrequency ablation and cryoablation show promising results for the treatment of RCCs associated with BHD syndrome. Percutaneous thermal ablation may be a useful treatment option for this rare hereditary condition.

AB - Purpose: The purpose of this study was to analyze the outcome of patients with Birt–Hogg–Dubé (BHD) syndrome who underwent percutaneous thermal ablation of renal cell carcinoma (RCC). Materials and methods: Six patients with genetically proven BHD syndrome who underwent one or more sessions of percutaneous thermal ablation for the treatment of RCC were included. There were 4 men and 2 women, with a mean age of 57.3 ± 7.5 [SD] years (range: 44–67 years). A total of 29 RCCs (1–16 tumors per patient) were treated during 20 thermal ablation sessions (7 with radiofrequency ablation and 13 with cryoablation). Outcomes of thermal ablation therapy were assessed, including technical success, adverse events, local tumor progression, development of metastases, survival after thermal ablation, and changes in renal function. Results: Technical success was achieved in all ablation sessions (success rate, 100%). No grade 4 or 5 adverse events were observed. All patients were alive with no distant metastasis during a median follow-up period of 54 months (range: 6–173 months). No local tumor progression was found. The mean decrease in estimated glomerular filtration rate during follow-up was 10.7 mL/min/1.73 m2. No patients required dialysis or renal transplantation. Conclusion: Radiofrequency ablation and cryoablation show promising results for the treatment of RCCs associated with BHD syndrome. Percutaneous thermal ablation may be a useful treatment option for this rare hereditary condition.

KW - Birt–Hogg–Dubé syndrome

KW - Cryoablation

KW - Percutaneous thermal ablation

KW - Radiofrequency ablation

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85068526357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068526357&partnerID=8YFLogxK

U2 - 10.1016/j.diii.2019.06.009

DO - 10.1016/j.diii.2019.06.009

M3 - Article

C2 - 31302073

AN - SCOPUS:85068526357

JO - Diagnostic and interventional imaging

JF - Diagnostic and interventional imaging

SN - 2211-5684

ER -